Results 81 to 90 of about 5,803 (182)
DEVELOPMENT AND VALIDATION OF STABILITY INDICATING RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF SOFOSBUVIR AND LEDIPASVIR IN TABLET DOSAGE FORM [PDF]
, 2018 Simple, specific, accurate and precise reversed phase high pressure liquid chromatographic method has been developed for the simultaneous determination of Sofosbuvir and Ledipasvir in tablet dosage form by reversed phase C18 column (Kromasil C18 5μ, 250 ...
M.Prasanthi Evangelin*, S.Manohar Babu, Konda Ravi Kumar
core +1 more source
ClinicoEconomics and Outcomes Research, 2018 Katherine Heath1,2 1Mathematical Ecology Research Group, Department of Zoology, University of Oxford, Oxford OX1 3PS, UK; 2New College, Oxford OX1 3BN, UK Background: Cost-benefit analyses are crucial to inform treatment policies, particularly when the ...
Heath K
doaj
Annals of Hepatology, 2017 Introduction: Recurrence of HCV infection in patients with chronic hepatitis C virus (HCV) at the time of liver transplantation is nearly universal and reduces the likelihood of graft and patient survival.
Eric M. Yoshida +19 more
doaj +1 more source
, 2019 The fixed-dose ledipasvir-sofosbuvir combination offers an effective and well-tolerated pill for the treatment of chronic hepatitis C infection. Only a few analytical works were carried out to estimate the Ledipasvir and Sofosbuvir drug combination in ...
Ismail, Yehea
core +1 more source
Prices that make sofosbuvir/ledipasvir cost-effective, by four economic regions in China.
, 2016 Prices that make sofosbuvir/ledipasvir cost-effective, by four economic regions in China.
Hui Zhuang (139189) +34 more
core +1 more source
Journal of Transplantation, 2018 Background. Since the introduction of direct antiviral agents (DAAs), morbidity of HCV has considerably decreased but still no guidelines have been formulated in renal transplant recipients (RTRs). We studied efficacy and tolerability of direct antiviral
Sourabh Sharma +4 more
doaj +1 more source
The baseline characteristics of the patients who were treated with sofosbuvir/ledipasvir (n = 493).
, 2018 The baseline characteristics of the patients who were treated with sofosbuvir/ledipasvir (n = 493).
Takeshi Kure (5328974) +16 more
core +1 more source
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease [PDF]
, 2015 Background & AimsThere are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have advanced liver disease.MethodsIn this phase 2, open-label study, we assessed treatment with the NS5A inhibitor ledipasvir, the ...
Muir, Andrew J. +64 more
core +1 more source
, 2017 Background and Aim:Pegylated-interferon-alpha plus ribavirin is the current standard-of-care regimen for treating chronic hepatitis C virus (HCV) infection in Taiwan; however, interferon-based regimens can be poorly tolerated.
Chuang, Wan-Long;Chien, Rong-Nan;Peng, Cheng-Yuan;Chang, Ting-Tsung;Lo, Gin-Ho;Sheen, I-Shyan;Wang, Horng-Yuan;Chen, Jyh-Jou;Yang, Jenny C.;Knox, Steven J.;Gao, Bing;Garrison, Kimberly L.;Mo, Hongmei;Pang, Phillip S.;Hsu, Yu-Chun;Hu, Tsung-Hui;Chu, Chi-Jen;Kao, Jia-Horng +1 more
core +1 more source
ICERs of sofosbuvir/ledipasvir compared to pegIFN plus RBV, by four economic regions in China.
, 2016 ICERs of sofosbuvir/ledipasvir compared to pegIFN plus RBV, by four economic regions in China.
Hui Zhuang (139189) +34 more
core +1 more source